| Rat Target Sites | Mouse Target Sites | TD50 (mg/kg/day) | |||
| Male | Female | Male | Female | Rat | Mouse |
| liv pan | liv | liv | no positive | 40.8m | 141 |
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
CHLORENDIC ACID 115-28-6 1219 M f b6c eat 24m24 TR304 : 0 79.1mg 160.mg lun MXA # 343.mg * P<.003 - 153.mg 1.94gm 1/50 5/50 6/50 lun:a/a,a/c. S lun a/a 412.mg * P<.002 177.mg 1.68gm 0/50 4/50 4/50 S MXA hes 1.17gm * P<.03 367.mg n.s.s. 0/50 1/50 3/50 mey:hes; spl:hes. S TBA MXB 87.1mg / P<.0005 46.6mg 350.mg 29/50 32/50 32/50 liv MXB 348.mg * P<.02 150.mg 52.5gm 3/50 7/50 7/50 liv:hpa,hpc,nnd. lun MXB 343.mg * P<.003 153.mg 1.94gm 1/50 5/50 6/50 lun:a/a,a/c. 1220 M m b6c eat 24m24 TR304 : 0 73.0mg 149.mg liv MXA 141.mg * P<.004 c 72.2mg 1.17gm 13/50 23/50 27/50 liv:hpa,hpc. liv hpc 206.mg * P<.009 c 101.mg 8.47gm 9/50 17/50 20/50 liv hpa 387.mg * P<.08 c 150.mg n.s.s. 5/50 9/50 10/50 thy fca 1.59gm * P<.04 474.mg n.s.s. 0/50 0/50 3/50 S TBA MXB 227.mg * P<.2 74.7mg n.s.s. 35/50 31/50 39/50 liv MXB 141.mg * P<.004 72.2mg 1.17gm 13/50 23/50 27/50 liv:hpa,hpc,nnd. lun MXB no dre P=1. 379.mg n.s.s. 15/50 4/50 9/50 lun:a/a,a/c. 1221 R f f34 eat 24m24 TR304 : 0 30.7mg 61.9mg liv MXA 98.8mg * P<.0005 c 56.0mg 283.mg 1/50 5/50 16/50 liv:hpc,nnd. liv nnd 162.mg * P<.004 c 80.3mg 1.11gm 1/50 3/50 11/50 liv hpc 271.mg * P<.02 c 122.mg n.s.s. 0/50 3/50 5/50 TBA MXB no dre P=1. 41.7mg n.s.s. 48/50 48/50 48/50 liv MXB 98.8mg * P<.0005 56.0mg 283.mg 1/50 5/50 16/50 liv:hpa,hpc,nnd. 1222 R m f34 eat 24m24 TR304 : 0 24.5mg 49.5mg MXB MXB 25.4mg * P<.0005 16.2mg 57.9mg 2/50 22/50 23/50 liv:nnd; pan:ana. C liv nnd 25.7mg * P<.0005 c 16.3mg 58.7mg 2/50 21/50 23/50 liv MXA 32.2mg * P<.002 18.2mg 127.mg 5/50 22/50 23/50 liv:hpc,nnd. S pan ana 131.mg * P<.005 c 63.4mg 1.04gm 0/50 4/50 6/50 lun MXA 148.mg * P<.01 69.7mg 10.1gm 0/50 4/50 5/50 lun:a/a,a/c. S lun a/a 168.mg * P<.01 e 75.9mg 8.53gm 0/50 3/50 5/50 pre MXA 59.4mg \ P<.02 26.2mg n.s.s. 1/50 10/50 (4/50) pre:adn,can,sqp. S sub fbs 380.mg * P<.05 130.mg n.s.s. 0/50 1/50 3/50 S pre can 189.mg * P<.2 e 68.2mg n.s.s. 1/50 8/50 4/50 TBA MXB no dre P=1. 25.7mg n.s.s. 50/50 49/50 50/50 liv MXB 32.2mg * P<.002 18.2mg 127.mg 5/50 22/50 23/50 liv:hpa,hpc,nnd.
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.